The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $399,100 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. This 2-year project will investigate how the pathogen Chlamydia trachomatis manipulates the host cell protein PICALM to facilitate its own replication and survival, while minimizing host cell stress. The research aims...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $130,950 to the Regents of the University of Idaho to conduct research on understanding the regulation of gene expression and the function of type III secretion system translocons in the developmental cycle of chlamydial bacteria. The research aims to provide a more complete understanding of the chlamydial developmental cycle, which...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Idaho. The grant will fund research to better understand the developmental cycle of chlamydial bacteria, which cause various infectious diseases in humans. Specifically, the project aims to develop a CRISPR-based knockdown screen to assess the role of essential genes in regulating chlamydial...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research into the regulation of divisome assembly in the obligate intracellular pathogen Chlamydia trachomatis. The total award is $782,795.00 over a period of 5 years, starting on Jun 17, 2025. The research aims to define the molecular mechanisms that regulate divisome function and the polarized division...
This $617,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to delineate the molecular function and contributions to species-specific infection biology of putative glycosyltransferase "cytotoxin" proteins in Chlamydia bacteria. The University of Kentucky Research Foundation, the awardee, has applied genetic and biochemical approaches to investigate...
This $145,745 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Oklahoma State University to investigate how the Chlamydia trachomatis bacterium, the leading cause of sexually transmitted infections worldwide, modulates the host's immune response and inflammasome activation. The research aims to elucidate the mechanism by which a specific Chlamydia protein, CT226, interacts with host...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $423,500.00 to investigate the role(s) of chlamydial polymorphic membrane proteins (PMPs) during infection with Chlamydia trachomatis. The award was granted to The University of Kentucky Research Foundation on July 1, 2025 and is set to run through June 30, 2027. The key objectives are to delineate the specific function(s) of PmpI...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,730 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin - Madison. The 5-year grant, effective from December 1, 2024 to November 30, 2029, will support research to elucidate the mechanisms by which prophages (viral DNA) in the gut symbiont Limosilactobacilus reuteri modulate the production of the antimicrobial compound reuterin. The research aims to...
The University of Chicago was awarded a $506,394 Project Grant by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 24, 2025. The grant supports research to define the mechanisms by which bacterial cholesterol-dependent cytolysins can reorganize host cell organelles and activate the NLRP3 inflammasome signaling pathway, which plays a critical role in the immune response to bacterial infections. The research aims to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $812,603 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Houston System. The grant aims to develop selective calcium-dependent protein kinase 1 (CDPK1) inhibitors that can efficiently access the gastrointestinal system to treat cryptosporidiosis, a significant public health threat with limited treatment options. The research will focus on structure-activity...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $775,795 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The grant, effective August 19, 2024 through June 30, 2029, supports research to investigate the functional relevance of polymorphisms in the tryptophan (TRP) operon of the pathogen Chlamydia trachomatis. Key focus areas include understanding the regulation of tryptophan biosynthesis genes by transcriptional and translational control mechanisms, and exploring how these regulatory systems enable C. trachomatis to adapt to nutrient-limited environments. The research aims to elucidate the role of the TRP operon and iron-responsive regulators in the pathogen's interaction with the host microbiome and nutrient acquisition strategies.